Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Jun;68(3):126-134.
doi: 10.1007/s12026-020-09131-x.

Jeffrey's insights: Jeffrey Modell Foundation's global genetic sequencing pilot program to identify specific primary immunodeficiency defects to optimize disease management and treatment

Affiliations
Observational Study

Jeffrey's insights: Jeffrey Modell Foundation's global genetic sequencing pilot program to identify specific primary immunodeficiency defects to optimize disease management and treatment

Jessica Quinn et al. Immunol Res. 2020 Jun.

Abstract

Primary immunodeficiencies (PI) are genetic defects of the immune system that result in chronic and often life-threatening infections and/or life-threatening autoimmunity if not diagnosed and treated. Patients with a suspected PI, but without a genetic diagnosis, commonly undergo a diagnostic odyssey that is costly, time-consuming, and arduous. This delay in diagnosis prevents appropriate disease management and treatment, contributing to prolonged suffering and decreased quality of life. Although next generation sequencing (NGS) can provide these patients with relief from such a diagnostic odyssey, it is often unavailable, mainly due to cost and inaccessibility. In January 2019, the Jeffrey Modell Foundation (JMF) launched a free genetic sequencing pilot program for Jeffrey Modell Centers Network (JMCN) patients clinically diagnosed with an underlying PI. A total of 21 sites within the JMCN were invited to participate. JMF collaborated with Invitae, and testing was comprised of Invitae's Primary Immunodeficiency Panel, which currently includes 207 genes. A questionnaire was disseminated to each participating physician to evaluate barriers to access to genetic sequencing and changes in disease management and treatment after testing. One hundred fifty-eight patients and 29 family members were tested in this pilot study. Twenty-one percent of patients with a suspected monogenic disorder received a molecular diagnosis, and others received potentially useful diagnostic leads. Based on the results of genetic sequencing, clinical diagnosis was altered in 45% of patients, disease management was altered in 40%, treatment was altered in 36%, and genetic counseling was altered in 62%. The results of this pilot program demonstrate the utility, cost-efficiency, and critical importance of NGS for PI and make the case for broad scale sequence-based diagnostics for PI patients when requested by expert immunologists.

Keywords: Gene sequencing; Genetic sequencing; Jeffrey Modell Centers Network (JMCN); Jeffrey Modell Foundation (JMF); Next generation sequencing (NGS); Primary immunodeficiency (PI); Sequencing.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest except for the following:

Jordan Orange, MD, PhD, Takeda Consultant, Enzyvant Consultant, received speaking honoraria from Takeda, ADMA Scientific Advisory Board, author and editor in immunology for Up To Date receiving royalties. Jennifer Holle, Rebecca Truty, Swaroop Aradhya, and Britt Johnson are current salaried employees of Invitae, including stock benefits.

Figures

Fig. 1
Fig. 1
Clinical results

References

    1. Modell V. The impact of physician education and public awareness on early diagnosis of primary immunodeficiencies. Immunol Res. 2007;38:43–47. doi: 10.1007/s12026-007-0048-5. - DOI - PubMed
    1. Modell F. Immunology today and new discoveries: building upon legacies of Dr. Robert A. Good. Immunol Res. 2007;38:48–50. doi: 10.1007/s12026-007-0049-4. - DOI - PubMed
    1. Cunningham-Rundles C, Ponda PP. Molecular defects in T- and B-cell primary immunodeficiency diseases. Nat Rev Immunol. 2005;5:880–892. doi: 10.1038/nri1713. - DOI - PubMed
    1. Cooper MA, Pommering TL, Koranyi K. Primary immunodeficiencies. Am Fam Physician. 2003;68:2001–2008. - PubMed
    1. BousfihaA JL, Al-HerzW AF, Casanova JL, Chatila T, et al. The 2015 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2015;35:727–738. doi: 10.1007/s10875-015-0198-5. - DOI - PMC - PubMed

Publication types

MeSH terms